全文获取类型
收费全文 | 4594篇 |
免费 | 350篇 |
国内免费 | 24篇 |
专业分类
耳鼻咽喉 | 26篇 |
儿科学 | 93篇 |
妇产科学 | 79篇 |
基础医学 | 742篇 |
口腔科学 | 100篇 |
临床医学 | 440篇 |
内科学 | 975篇 |
皮肤病学 | 191篇 |
神经病学 | 618篇 |
特种医学 | 203篇 |
外科学 | 411篇 |
综合类 | 18篇 |
一般理论 | 5篇 |
预防医学 | 344篇 |
眼科学 | 60篇 |
药学 | 347篇 |
中国医学 | 7篇 |
肿瘤学 | 309篇 |
出版年
2024年 | 1篇 |
2023年 | 57篇 |
2022年 | 42篇 |
2021年 | 164篇 |
2020年 | 139篇 |
2019年 | 172篇 |
2018年 | 198篇 |
2017年 | 163篇 |
2016年 | 174篇 |
2015年 | 198篇 |
2014年 | 213篇 |
2013年 | 286篇 |
2012年 | 427篇 |
2011年 | 427篇 |
2010年 | 262篇 |
2009年 | 224篇 |
2008年 | 342篇 |
2007年 | 284篇 |
2006年 | 283篇 |
2005年 | 227篇 |
2004年 | 181篇 |
2003年 | 176篇 |
2002年 | 129篇 |
2001年 | 29篇 |
2000年 | 16篇 |
1999年 | 26篇 |
1998年 | 33篇 |
1997年 | 21篇 |
1996年 | 17篇 |
1995年 | 10篇 |
1994年 | 6篇 |
1993年 | 8篇 |
1992年 | 5篇 |
1991年 | 4篇 |
1990年 | 2篇 |
1989年 | 3篇 |
1988年 | 4篇 |
1986年 | 1篇 |
1984年 | 1篇 |
1982年 | 4篇 |
1980年 | 1篇 |
1976年 | 1篇 |
1975年 | 1篇 |
1974年 | 2篇 |
1929年 | 2篇 |
1924年 | 2篇 |
排序方式: 共有4968条查询结果,搜索用时 31 毫秒
1.
ABSTRACTWhile prior research has demonstrated the benefits of self-affirming individuals prior to exposing them to potentially threatening health messages, the current study assesses the feasibility of inducing self-affirmation vicariously through the success of a character in a narrative. In Study 1, college-age participants who regularly use e-cigarettes (N = 225) were randomly assigned to read one of two versions of a story depicting a college student of their own gender. The versions were identical except in the vicarious self-affirmation (VSA) condition, the main character achieves success (i.e., honored with a prestigious award) before being confronted by a friend about the dangers associated with their e-cigarette use; whereas in the vicarious control condition, the achievement is mentioned after the risk information. Results of the posttest and 10-day follow-up demonstrated that VSA reduced messages derogation, while increasing self-appraisal and perceived risk. The effect of VSA on e-cigarette outcomes was moderated by frequency of use, with heavier users benefiting the most. Study 2 (N = 152) confirmed that traditional value affirmation works with our stimuli on a comparable population. 相似文献
2.
Theresa M. Thole Joern Toedling Annika Sprüssel Sebastian Pfeil Larissa Savelyeva David Capper Clemens Messerschmidt Dieter Beule Stefanie Groeneveld-Krentz Cornelia Eckert Guido Gambara Anton G. Henssen Sabine Finkler Johannes H. Schulte Anja Sieber Nils Bluethgen Christian R. A. Regenbrecht Annette Künkele Marco Lodrini Angelika Eggert Hedwig E. Deubzer 《International journal of cancer. Journal international du cancer》2020,146(4):1031-1041
Accurate modeling of intratumor heterogeneity presents a bottleneck against drug testing. Flexibility in a preclinical platform is also desirable to support assessment of different endpoints. We established the model system, OHC-NB1, from a bone marrow metastasis from a patient diagnosed with MYCN-amplified neuroblastoma and performed whole-exome sequencing on the source metastasis and the different models and passages during model development (monolayer cell line, 3D spheroid culture and subcutaneous xenograft tumors propagated in mice). OHC-NB1 harbors a MYCN amplification in double minutes, 1p deletion, 17q gain and diploid karyotype, which persisted in all models. A total of 80–540 single-nucleotide variants (SNVs) was detected in each sample, and comparisons between the source metastasis and models identified 34 of 80 somatic SNVs to be propagated in the models. Clonal reconstruction using the combined copy number and SNV data revealed marked clonal heterogeneity in the originating metastasis, with four clones being reflected in the model systems. The set of OHC-NB1 models represents 43% of somatic SNVs and 23% of the cellularity in the originating metastasis with varying clonal compositions, indicating that heterogeneity is partially preserved in our model system. 相似文献
3.
4.
Florian Huemer Thomas Melchardt Bettina Jansko Adam Wahida Stefanie Jilg Philipp J. Jost Eckhard Klieser Katja Steiger Teresa Magnes Lisa Pleyer Sigrun Greil‐Ressler Christof Rass Richard Greil Alexander Egle 《European journal of haematology》2019,102(5):437-441
Acute myeloid leukemia (AML) is a disease of the elderly population and survival remains poor after failure of hypomethylating agents (HMA). The BCL‐2 inhibitor venetoclax demonstrated activity as monotherapy and in combination with chemotherapy or HMA in AML. In this case series, patients with secondary AML (sAML) not eligible for intensive chemotherapy and refractory to HMA were treated with venetoclax within a named patient program at our tertiary cancer center in Salzburg, Austria. Between April 2017 and September 2018, seven patients with sAML received venetoclax therapy. Two out of seven patients achieved a complete remission upon venetoclax initiation with a PFS of 505 days and 352 days and another patient achieved complete peripheral blood blast clearing within nine days after start of venetoclax. Among the venetoclax responders, primary refractory disease to prior HMA therapy was documented, 2 patients harbored IDH1/IDH2 mutations and one patient had an antecedent myeloproliferative neoplasm. High BCL‐2 and/or BIM expression in myeloblasts was found in venetoclax responders and response was significantly associated with overall survival (responders: 364 days versus non‐responders: 24 days, P = 0.018). Venetoclax monotherapy is safe and is able to induce durable responses in elderly patients with secondary AML after treatment failure with HMA. 相似文献
5.
6.
Schemm Stefanie A. Schemm Andreas Schwenkhagen Anneliese Schaudig Katrin 《Der Gyn?kologe》2019,52(6):463-472
Die Gynäkologie - Frauen im Erwachsenenalter mit einem angeborenen Herzfehler (EMAH) werden in Zukunft aufgrund des medizinischen Fortschritts eine immer größere Patientinnengruppe... 相似文献
7.
8.
Stefanie Linder Simone B. Duss Charles Dvok Christoph Merlo Stefan Essig Kali Tal Cinzia Del Giovane Lamprini Syrogiannouli Raphael Heinzer Christoph Nissen Claudio L. A. Bassetti Reto Auer Micheline Maire 《Journal of sleep research》2021,30(1):e13169
Guidelines recommend cognitive behavioural therapy for insomnia (CBT‐I) as first‐line treatment for chronic insomnia, but it is not clear how many primary care physicians (PCPs) in Switzerland prescribe this treatment. We created a survey that asked PCPs how they would treat chronic insomnia and how much they knew about CBT‐I. The survey included two case vignettes that described patients with chronic insomnia, one with and one without comorbid depression. PCPs also answered general questions about treating chronic insomnia and about CBT‐I and CBT‐I providers. Of the 820 Swiss PCPs we invited, 395 (48%) completed the survey (mean age 54 years; 70% male); 87% of PCPs prescribed sleep hygiene and 65% phytopharmaceuticals for the patient who had only chronic insomnia; 95% prescribed antidepressants for the patient who had comorbid depression. In each case, 20% of PCPs prescribed benzodiazepines or benzodiazepine receptor agonists, 8% prescribed CBT‐I, 68% said they knew little about CBT‐I, and 78% did not know a CBT‐I provider. In the clinical case vignettes, most PCPs treated chronic insomnia with phytopharmaceuticals and sleep hygiene despite their lack of efficacy, but PCPs rarely prescribed CBT‐I, felt they knew little about it, and usually knew no CBT‐I providers. PCPs need more information about the benefits of CBT‐I and local CBT‐I providers and dedicated initiatives to implement CBT‐I in order to reduce the number of patients who are prescribed ineffective or potentially harmful medications. 相似文献
9.
Sara Denicolò Paul Perco Stefanie Thöni Gert Mayer 《Journal of diabetes and its complications》2021,35(7):107931
Cardiovascular and renal complications are a major burden for individuals with type 2 diabetes mellitus (T2DM). Besides lifestyle interventions, current guidelines recommend combination drug therapy to prevent or delay the incidence and progression of comorbidities. However, non-adherence to pharmacotherapy is common in chronic conditions such as T2DM and a barrier to successful disease management. Numerous studies have associated medication non-adherence with worse outcome as well as higher health care costs. This narrative review provides (i) an overview on adherence measures used within and outside research settings, (ii) an estimate on the prevalence of non-adherence to antidiabetic and cardiovascular drugs in T2DM, and (iii) specifically focuses on the association of non-adherence to these drugs with renal and cardiovascular outcomes. 相似文献